Cracow University of Technology posted this:The new lupeol derivative and the method of obtaining.This invention relates to a biologically active compound, the derivative of natural triterpene lupeol. This derivative is active for human skin cells, improving their proliferation process. In addition, the substance has the ability to neutralize free radicals. The described derivative can be used as an active ingredient in pharmaceutical and cosmetic preparations dedicated for damaged or burned skin, as well as in anti-aging cosmetics.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers with polyphenolic groups. Uses as antioxidants and anticancer.The "Dendrimer for biomedical applications Research Group" at Alcalá University presents dendritic macromolecules with skeleton of carbosilane nature that contain in their structure polyphenolic groups (GPF). These compounds are powerful antioxidants and free radical scavengers, as well as anticancer agents, with application in sectors such as food, cosmetics and pharmaceutical industry. The invention provides a process for its procurance and uses.
University of Vigo posted this:Method for the sequential immunochemical evaluation on a same biological sample of NCAM (Neural Cell Adhesion Molecule) protein and its PolySialic Acid (PSA) tail, by western blot coupled to chemiluminiscence detection.The method optimizes the expression assays of PSA-NCAM isoforms in biological samples available in small quantities or restricted (as is the case of human specimens, for example). It improves quantitative and qualitative performance of PSA-NCAM analysis by western blot.
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
uacoopera posted this:Fluorescent compounds, methods of manufacturing and uses thereofA group of researchers from a Portuguese university developed a family of new fluorophores to be used in biological imaging, either in cells or in entire organisms, in fluorescence microscopy techniques, including live cell imaging. The fluorophores are not toxic to cells and organisms, and light up cells by binding to organelles such as the Golgi apparatus, nucleus, and particularly lipid droplets. Importantly, the fluorophores change color with the polarity of the environment. The university is looking for companies that would be interested in developing this technology further through partnership, or in commercializing the probes through licensing or acquisition of the patent.
JPT Peptide Technologies posted this:Custom Peptide SynthesisJPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT! Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
Creative Proteomics posted this:Proteomic ServiceCreative Proteomics specializes in a full range of services to support various proteome-related researches from identification of single proteins to large-scale proteomic studies. We have one of the most advanced proteomics platforms in the world and our staff scientists are experienced proteomics professionals.
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Innovative device for electro-mechanical stimulation for tissue engineering applicationsThe device presented enables the combination of both electrical and mechanical stimulation either independently or simultaneously. The mechanical stimulation is performed with a non-invasive and aseptic novel approach. A sterile, single use device is placed into a standard culture plate. The cells are seeded in a volume contained in the central area of the device, which goes through mechanical stimulation thanks to the embedded magnets and the external magnetic field.
Creative Proteomics posted this:2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARDCreative Proteomics provides a full range of drug development services, including Molecular Biology, Biochemistry, Systems Biology, Organic Chemistry, Genomics, Bioinformatics, Structural Biology, Preclinical and Clinical studies. Please contact us to know more about 2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARD!
Creative Peptides posted this:Catalog Peptides-Teduglutide cas 197922-42-2Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products. We provide Teduglutide. More information please visit the website:http://www.creative-peptides.com/product/teduglutide-item-m3412132-21367.html
RAMOT at Tel Aviv University Ltd. posted this:Novel Anti Bacterial DrugTwo non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit three antimicrobial activities: (a) it binds specifically to gram negative bacteria, thus enhancing penetration of antibiotics into the bacteria and (b) it promotes bacterial killing by blood phagocytes and (c) It binds to free LPS in the blood thus reduces effect on patients. Project ID : 10-2007-98
RAMOT at Tel Aviv University Ltd. posted this:GSK-3 Peptide Inhibitors for the Treatment of CNS Related DisordersNovel Glycogen synthase kinase 3 (GSK-3) inhibitors were developed. These inhibitors are substrate competitors that interact specifically with the GSK-3 substrate binding site. GSK-3, like other protein kinases, has a common structurally conserved catalytic domain that comprises the ATP-binding loop. The great majority of reported inhibitors developed to date are ATP-competitive compounds; however, such inhibitors demonstrate limited specificity, as the ATP-binding pocket is highly conserved among protein kinases. In contrast, the substrate binding site is more specific, and thus targeting inhibitors toward this domain yields more specific compounds. The strategy is based on exploiting the unique recognition motif of GSK-3 which comprises a phosphorylated residue and using molecular and computational analyses. Project ID : 10-2011-132